每经AI快讯，戴维医疗（SZ 300314，收盘价：14.15元）10月22日晚间发布三季度业绩公告称，2025年 前三季度营收约3.93亿元，同比减少2.55%；归属于上市公司股东的净利润约7262万元，同比增加 14.71%；基本每股收益0.2521元，同比增加14.7%。 每经头条（nbdtoutiao）——展望"十五五"|专访贺铿：必须改变以往将资金过度集中于房屋建设和基础 设施建设的倾向，更加突出民生领域投入 （记者 曾健辉） 截至发稿，戴维医疗市值为41亿元。 ...

人民财讯10月22日电，戴维医疗（300314）10月22日披露2025年三季度报告，公司第三季度实现营业收 入1.41亿元，同比增长3.13%；归母净利润2164.11万元，同比增长28.96%。前三季度实现营业收入3.93 亿元，同比下降2.55%；归母净利润7261.78万元，同比增长14.71%。 ...

证券代码：300314 证券简称：戴维医疗 公告编号：2025-069 宁波戴维医疗器械股份有限公司 与会监事一致认为：公司2025年第三季度报告的编制和审核程序符合 法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映 了公司2025年第三季度的实际情况，不存在任何虚假记载、误导性陈述或 者重大遗漏。 具体内容详见公司同日于中国证监会指定的创业板信息披露网站上 披露的《2025年第三季度报告》（公告编号：2025-067）。 本议案以3票同意，0票反对，0票弃权获得通过。 第五届监事会第十五次会议决议的公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 一、会议召开情况 宁波戴维医疗器械股份有限公司（以下简称"公司"）第五届监事会 第十五次会议于2025年10月22日在公司会议室以现场表决的方式召开。本 次会议于2025年10月16日以专人送达形式通知了全体监事。本次会议应参 与表决的监事3名，实际参与表决的监事3名，会议由监事会主席陈红主持。 本次会议的通知、召开以及参会监事人数均符合相关法律、法规及《公司 章程》等的有关规定。 二、会议审议 ...

证券代码：300314 证券简称：戴维医疗 公告编号：2025-068 宁波戴维医疗器械股份有限公司 第五届董事会第十五次会议决议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 本议案以9票同意、0票反对、0票弃权的表决结果获得通过。 二、会议审议情况 经与会董事认真审议，本次会议以记名投票的表决方式表决通过了以 下决议： 1、审议通过《关于公司 2025 年第三季度报告的议案》 董事会认为：公司2025年第三季度报告的编制符合法律、行政法规和 中国证监会的有关规定，报告内容真实、准确、完整地反映了公司2025 年第三季度的实际情况，不存在任何虚假记载、误导性陈述或重大遗漏。 具体内容详见公司同日于中国证监会指定的创业板信息披露网站上披 露的《2025年第三季度报告》（公告编号：2025-067）。 本议案已经公司第五届董事会审计委员会第十六次会议审议通过。 一、会议召开情况 宁波戴维医疗器械股份有限公司（以下简称"公司"）第五届董事会 第十五次会议于2025年10月22日上午在公司会议室以现场表决的方式召 开。应参加表决董事9人，实际参加表决董事9人 ...

Core Insights - The company reported third-quarter revenue of 141 million, representing a year-over-year increase of 3.13% [1] - Net profit for the third quarter was 21.64 million, showing a year-over-year growth of 28.96% [1] - For the first three quarters, total revenue was 393 million, reflecting a year-over-year decline of 2.55% [1] - Net profit for the first three quarters reached 72.62 million, which is a year-over-year increase of 14.71% [1]

Financial Performance - The company's operating revenue for Q3 2025 was ¥141,399,028.33, representing a 3.13% increase year-over-year, while the year-to-date revenue decreased by 2.55% to ¥392,655,821.72[5] - Net profit attributable to shareholders for Q3 2025 was ¥21,641,148.48, a significant increase of 28.96% compared to the same period last year, and a year-to-date increase of 14.71% to ¥72,617,842.77[5] - Basic earnings per share for Q3 2025 was ¥0.0751, up 28.82% year-over-year, with diluted earnings per share also at ¥0.0751[5] - Total operating revenue for the current period is CNY 392,655,821.72, a decrease of 2.8% from CNY 402,925,721.56 in the previous period[18] - Net profit for the current period is CNY 72,617,842.77, an increase of 14.5% compared to CNY 63,307,872.06 in the previous period[19] - Earnings per share (EPS) increased to CNY 0.2521 from CNY 0.2198, representing a growth of 14.4%[20] Assets and Liabilities - Total assets at the end of Q3 2025 reached ¥1,443,616,126.33, reflecting a 2.38% increase from the end of the previous year[5] - Current assets totaled CNY 879,256,716.39, down from CNY 901,714,271.97 at the beginning of the period, indicating a decrease of approximately 2.5%[14] - Non-current assets increased to CNY 564,359,409.94 from CNY 508,368,642.73, reflecting a growth of about 11%[15] - The total liabilities decreased to CNY 216,567,496.67 from CNY 232,387,523.93, showing a reduction of approximately 6.8%[15] - Total liabilities decreased to CNY 225,021,267.57 from CNY 241,765,545.70, a reduction of 6.9%[16] Cash Flow - The company's cash flow from operating activities for the year-to-date period was ¥14,804,238.40, showing a 5.51% increase[5] - Cash flow from operating activities generated a net amount of CNY 14,804,238.40, slightly up from CNY 14,030,641.34 in the previous period[21] - Cash and cash equivalents at the end of the period were CNY 391,479,629.63, up from CNY 345,230,914.85, indicating an increase of approximately 13.4%[14] Investments - Investment income for Q3 2025 was ¥12,924,163.21, a remarkable increase of 1,579.01% compared to the previous period[8] - Investment income improved significantly to CNY 12,924,163.21 from a loss of CNY 873,836.79 in the previous period[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 20,297, with the top shareholder holding 45.81% of the shares[9] - Total equity attributable to shareholders increased to CNY 1,218,594,858.76 from CNY 1,168,317,369.00, reflecting a growth of 4.0%[16] Other Financial Metrics - The company received government subsidies amounting to ¥2,107,947.15 during the reporting period, contributing to its financial performance[6] - Other income rose to CNY 9,284,788.67 from CNY 7,517,469.38, an increase of 23.5%[19] - Deferred income increased to CNY 3,850,905.84 from CNY 3,371,835.46, marking a rise of 14.2%[16] Operational Changes - The company reported a 49.16% increase in accounts receivable, totaling ¥39,412,724.03, primarily due to increased credit limits for distributors[8] - The company experienced a 69.76% increase in prepayments, amounting to ¥20,208,693.76, attributed to higher prepayments for testing, exhibitions, and consulting services[8] - Inventory increased to CNY 219,844,431.26 from CNY 182,135,010.43, marking a growth of about 20.7%[14] - The company’s long-term equity investments decreased slightly to CNY 48,372,544.79 from CNY 50,327,967.68, a decline of about 3.9%[15] Audit Information - The company did not undergo an audit for the third quarter financial report[23]

Group 1 - Pinggao Electric reported a 6.98% increase in revenue to 8.436 billion yuan and a 14.62% increase in net profit to 982 million yuan for the first three quarters of 2025 [1] - Wanchen Group achieved a 77.37% increase in revenue to 36.562 billion yuan and a staggering 917.04% increase in net profit to 855 million yuan for the first three quarters of 2025 [2] - Xintian's revenue decreased by 10.42% to 481 million yuan, with a net profit decline of 35.19% to 91.9 million yuan for the first three quarters of 2025 [3] Group 2 - Chuangye Heima reported a revenue drop of 35.68% to 102 million yuan and a net loss of 24.93 million yuan for the first three quarters of 2025 [4] - Huaxin New Materials saw a 16.11% increase in revenue to 265 million yuan and an 18.56% increase in net profit to 40.81 million yuan for the first three quarters of 2025 [5] - Meihua Medical's revenue increased by 3.28% to 1.194 billion yuan, but net profit fell by 19.25% to 208 million yuan for the first three quarters of 2025 [6] Group 3 - Silica Technology reported a 24.30% increase in revenue to 2.651 billion yuan and a 44.63% increase in net profit to 229 million yuan for the first three quarters of 2025 [7] - Anada experienced a revenue decline of 6.03% to 1.31 billion yuan and a net loss of 46.37 million yuan for the first three quarters of 2025 [8] - StarNet Ruijie achieved a 19.20% increase in revenue to 14.168 billion yuan and a 31.06% increase in net profit to 344 million yuan for the first three quarters of 2025 [9] Group 4 - New Link Electronics reported a revenue decrease of 0.37% to 550 million yuan but a significant net profit increase of 421.43% to 535 million yuan for the first three quarters of 2025 [10] - Tianyin Electromechanical's revenue fell by 22.75% to 581 million yuan, with a net profit decline of 56.10% to 24.27 million yuan for the first three quarters of 2025 [11] - Hengtong Co. reported a revenue decrease of 39.29% to 1.05 billion yuan, but a net profit increase of 78.33% to 176 million yuan for the first three quarters of 2025 [12] Group 5 - Xigao Institute achieved a 15.05% revenue increase to 651 million yuan and a 21.28% net profit increase to 198 million yuan for the first three quarters of 2025 [13] - Good Housewife reported a revenue decrease of 0.91% to 1.059 billion yuan and a net profit decline of 24.79% to 143 million yuan for the first three quarters of 2025 [14] - China Pharmaceutical's subsidiary received approval for Vitamin B6 injection, indicating a positive development in its product pipeline [20] Group 6 - Xi Zhong Technology received approval for the issuance of convertible bonds, indicating potential for future capital raising [22] - Chengda Bio signed a strategic cooperation agreement with the Chinese Academy of Microbiology, focusing on infectious disease prevention [25] - Fuyuan Pharmaceutical received a drug registration certificate for Dydrogesterone tablets, enhancing its product offerings [26] Group 7 - Zhehai Deman received 8.1202 million yuan in land acquisition compensation, indicating a successful resolution of land-related issues [27] - Zhongjin Irradiation announced the resignation of its deputy general manager, indicating potential changes in management [29] - Hendi Pharmaceutical received a drug registration certificate for Febuxostat tablets, expanding its product portfolio [30] Group 8 - David Medical's subsidiary received a medical device registration certificate for a surgical stapler, enhancing its product offerings [32] - Liaoning Energy announced plans for a share reduction by a major shareholder, indicating potential changes in ownership structure [34] - Fengyuan Co. signed a framework agreement for the supply of lithium iron phosphate, indicating growth in its supply chain [35] Group 9 - Shengda Resources announced the resumption of construction at a mining site, indicating recovery from previous operational disruptions [37] - Shiyuan Co. reported a revenue increase of 5.45% to 18.087 billion yuan, but a net profit decline of 6.81% to 867 million yuan for the first three quarters of 2025 [39] - Feilida reported a revenue decrease of 6.81% to 4.659 billion yuan, but a net profit increase of 49.1% to 33.19 million yuan for the first three quarters of 2025 [40] Group 10 - Changyuan Donggu reported a revenue increase of 29.75% to 1.648 billion yuan and a net profit increase of 76.71% to 274 million yuan for the first three quarters of 2025 [41] - Liyuanheng reported a net profit of 47.49 million yuan for the first three quarters of 2025, indicating stable performance [42] - Fangyuan Co. reported a net loss of 121 million yuan for the first three quarters of 2025, indicating challenges in its operations [43] Group 11 - China Mobile reported a revenue increase of 0.4% to 794.7 billion yuan and a net profit increase of 4% to 115.4 billion yuan for the first three quarters of 2025 [44] - Huangshanghuang reported a revenue decrease of 5.08% to 1.379 billion yuan but a net profit increase of 28.59% to 101 million yuan for the first three quarters of 2025 [46] - Youcai Resources announced plans to invest approximately 150 million yuan in a new materials production base project [47] Group 12 - Huawei Technology announced plans to invest up to 20 million euros in two German subsidiaries [49] - China Shipbuilding projected a net profit increase of 144.42% to 170.85% for the first three quarters of 2025, indicating strong performance [51] - Aeston's subsidiary plans to transfer a 48% stake in a company for 245 million yuan, indicating strategic divestment [52] Group 13 - Jinxinno plans to raise up to 292 million yuan through a private placement, indicating potential for expansion [53] - China Power Construction reported a 5.04% increase in new contract amounts to 904.527 billion yuan for the first three quarters of 2025 [54] - Helitai reported a net profit increase of 101.45% to 17.81 million yuan for the first three quarters of 2025 [55] Group 14 - Xuefeng Technology reported a revenue decrease of 8.28% to 4.183 billion yuan and a net profit decline of 34.6% to 394 million yuan for the first three quarters of 2025 [57] - Juzhi Technology reported a revenue increase of 21.40% to 615 million yuan and a net profit increase of 33.78% to 82.47 million yuan for the first three quarters of 2025 [59] - Jinxi Axle reported a revenue decrease of 0.11% to 872 million yuan but a net profit increase of 268.03% to 22.11 million yuan for the first three quarters of 2025 [60] Group 15 - Longsheng Technology reported a revenue increase of 10.13% to 1.810 billion yuan and a net profit increase of 36.89% to 210 million yuan for the first three quarters of 2025 [62] - Shannon Chip Creation announced plans for a share reduction by a major shareholder, indicating potential changes in ownership structure [63]

Group 1 - David Medical announced that its wholly-owned subsidiary, Ningbo Weierkaidi Medical Devices Co., Ltd., received a medical device registration certificate from the Zhejiang Provincial Drug Administration for a product named "Disposable Endoscopic Linear Cutting Stapler and Components" [1] Group 2 - The article emphasizes the need to shift funding focus from excessive investment in housing and infrastructure to enhancing investment in the livelihood sector [1]

Core Viewpoint - David Medical (300314.SZ) announced that its wholly-owned subsidiary, Ningbo Weier Kaidi Medical Devices Co., Ltd., has received a medical device registration certificate from the Zhejiang Provincial Drug Administration for a disposable laparoscopic linear cutting stapler and its components, marking a significant advancement in minimally invasive surgical instruments [1] Group 1 - The registered product is a disposable laparoscopic linear cutting stapler, which is an important instrument in laparoscopic surgery [1] - This device replaces traditional manual suturing and utilizes titanium staples to cut or join tissues, offering advantages such as reduced surgical trauma, shorter operation time, and faster postoperative recovery [1] - Laparoscopic staplers are increasingly used in general surgery and thoracic surgery for minimally invasive procedures [1]

注册证编号：浙械注准20252021809 证券代码：300314 证券简称：戴维医疗 公告编号：2025-066 宁波戴维医疗器械股份有限公司 关于全资子公司产品获得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 宁波戴维医疗器械股份有限公司（以下简称"公司"）全资子公司宁 波维尔凯迪医疗器械有限公司（以下简称"维尔凯迪"）于近日收到浙江 省药品监督管理局颁发的1项《医疗器械注册证》，具体如下： 一、医疗器械注册证的具体情况 产品名称：一次性使用腔镜直线型切割吻合器及组件 三、对公司的影响 以上产品医疗器械注册证的取得，有利于丰富公司产品线，进一步提 高公司的核心竞争力，对公司未来的经营成果将产生积极影响。 四、风险提示 目前尚无法预测该等产品对公司未来营业收入的影响，敬请投资者注 意投资风险。 特此公告。 批准日期：2025年10月17日 有效期至：2030年10月16日 注册分类：Ⅱ类 适用范围：用于腔镜下消化道重建及脏器切除手术中的残端或切口的 闭合。 二、新产品的市场状况 维尔凯迪本次获注册的一次性使用腔镜直线型切割吻合器及组件 ...